<DOC>
	<DOCNO>NCT00783094</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled , parallel-design compare efficacy safety tadalafil once-a-day dose versus placebo 12 week follow open-label extension evaluate long-term safety efficacy tadalafil Japanese men sign symptom benign prostatic hyperplasia .</brief_summary>
	<brief_title>Study Tadalafil Once-a-Day 12 Weeks Japanese Men With Benign Prostatic Hyperplasia Followed Open-Label Extension</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Japanese Males , 45 year old old , benign prostatic hyperplasia ( BPH ) least 6 month prior Visit 1 International Prostate Symptom Score ( IPSS ) great equal 13 Visit 2 . Agree use approve experimental pharmacologic BPH , erectile dysfunction ( ED ) , and/or overactive bladder ( OAB ) treatment time study . Have take Finasteride Dutasteride therapy , Antiandrogenic hormone BPH therapy , ED OAB therapy specify duration time prior Visit 2 . Prostate specific antigen ( PSA ) score beyond acceptable range define study Visit 1 . History urinary retention lower urinary tract ( bladder ) stone within 6 month Visit 1 . History urethral obstruction due stricture , valve , sclerosis , tumor Visit 1 . Clinical evidence prostate cancer Visit 1 . Clinical evidence bladder urinary tract condition , may affect low urinary tract symptom Visit 1 . History cardiac condition , include Angina require certain treatment nitrate , unstable angina define study , positive cardiac stress test start study . History significant central nervous system ( CNS ) injury ( include stroke spinal cord injury ) within 6 month Visit 1 . Use nitrate , cancer chemotherapy , androgen , antiandrogens , estrogen , luteinizing hormonereleasing hormone ( LHRH ) agonists/antagonists , anabolic steroid Visit 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>